Cancer Family
Stromal Neoplasm
CI-CAN-00000360Explore in graph →
Non-malignant52 active trials2 approved drugs89 evidence items
- NCIt
- C6781
Loading cancer entity…
Cancer Family
CI-CAN-00000360Explore in graph →
Clinical trials
355 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04924075 | Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) | recruiting | Phase 2 | 355 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Sep 25, 2026 | clinicaltrials |
| NCT05152472 | A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments(ATEZOGIST) | recruiting |
| Phase 2 |
| 110 |
| Centre Leon BerardOTHER |
| 1 |
| Sep 10, 2026 |
| clinicaltrials |
| NCT05493215 | Imatinib TDM in GIST | recruiting | Phase 2 | 28 | Reema A. PatelOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07406633 | KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) | recruiting | Phase 2 | 46 | Kumquat Biosciences Inc.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05957367 | A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 94 | Deciphera Pharmaceuticals, LLCINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT07379047 | Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)(GISTAR-1) | recruiting | Phase 2 / Phase 3 | 255 | Ningbo Newbay Technology Development Co., LtdINDUSTRY | 2 | Jun 10, 2026 | clinicaltrials |
| NCT07434843 | PH 2 Pemigatinib in SDH-deficient GIST(PEMIGIST) | recruiting | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05661643 | The Efficacy and Safety of Temozolomide in SDH-deficient GIST(GIST) | recruiting | Phase 2 | 29 | Asan Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05905887 | Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor | recruiting | Phase 2 | 48 | Asan Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06326346 | GIST Oral Paclitaxel(Liporaxel) | recruiting | Phase 2 | 28 | Asan Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07096609 | Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients(LONGIST) | recruiting | Phase 1 / Phase 2 | 48 | Asan Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03624244 | Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)(BFR-ESS) | recruiting | Phase 2 | 40 | Centre Leon BerardOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06630234 | A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) | recruiting | Phase 1 / Phase 2 | 120 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05366816 | ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST | recruiting | Phase 2 | 48 | University of MiamiOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05385549 | 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk | recruiting | Phase 2 | 35 | Asan Medical CenterOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT06277154 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 148 | HRYZ Biotech Co.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT05009927 | Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten) | recruiting | Phase 2 | 50 | Centre Leon BerardOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT04933669 | Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors(ZJGIST-01) | recruiting | Phase 2 | 122 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Oct 12, 2021 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials